(Q33775197)

English

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ihor Vynnychenko

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Ulrich Gatzemeier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Joachim von Pawel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Petr Zatloukal

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Filippo de Marinis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Wilfried E E Eberhardt

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Luis Paz-Ares

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Karl-Maria Schumacher

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thomas Goddemeier

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kenneth J O'Byrne

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Robert Pirker

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

17 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

30-37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapies in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor immune escape by the loss of homeostatic chemokine expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970278-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70278-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21169060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33775197&oldid=1611179681"